Bone Retention of Bisphosphonate (Zometa) in Patients With Multiple Myeloma or Breast Cancer With Metastases to Bone.

Trial Profile

Bone Retention of Bisphosphonate (Zometa) in Patients With Multiple Myeloma or Breast Cancer With Metastases to Bone.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Apr 2013

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Advanced breast cancer; Bone metastases; Multiple myeloma
  • Focus Biomarker; Pharmacokinetics
  • Most Recent Events

    • 29 Apr 2013 New information source identified and integrated European Clinical trials database
    • 29 Apr 2013 Status changed from recruiting to completed as reported by European Clinical Trials database.
    • 06 Jun 2011 Planned End Date changed from 1 Mar 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top